StockRing.com   Home    DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH   
  iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   
 4/18/2014, (NASDAQ:MRK), $56.47 +0.21, +0.37%, "BUY" Merck & Compan Stock
 




  
  

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

On   4/18/2014   StockRing.com recommends to   "BUY"   MRK   stock at current price of   $56.47.
Today MRK stock opened at $56.45 and was trading in the daily range of $ 250190 per share.
Merck & Compan (NASDAQ:MRK) Market capitalization is $166.1B. MRK average daily volume is N/A.
On last trading session MRK stock traded 11,263,810 shares. Also the Short Ratio for (NASDAQ:MRK) stock is 44.033B.
Last year Merck & Compan(NASDAQ:MRK) before taxes (EBITDA) (ttm) earned $57.01 on revenue of $3.31.
MRK 50-Day Moving Average is $15.668B vs. $56.47 now and 200-Day Moving Average is $56.17 vs. $56.47.
--------------------------------------------------------------------------------------------------------------------
VIX is "HOLD".  Nasdaq is "BUY".  S&P 500 is "BUY" on  4/17/2014
--------------------------------------------------------------------------------------------------------------------
MRK Earnings Per Share - EPS (ttm) is 1.47. MRK Stock Price Per Earnings ratio - P/E is 38.27.
Merck & Compan(NASDAQ:MRK) stock pays a dividend of $ " per share which is a yield of "NYSE"%.
On average analysts predict that One Year Target Estimated price for MRK stock is $51.46.
In the last 52 weeks MRK stock was trading in the range of $44.60 - 58.14.
 
 
  Our FREE iPhone App Buy-Sell-Hold ratings for 4459 stocks & ETFs:
 
1. DOW30+    Part 1    199 Stocks    Updated: 4/17/2014 1:36:28 AM
2. DOW30+    Part 2    192 Stocks    Updated: 4/17/2014 1:50:47 AM
3. DOW30+    Part 3    193 Stocks    Updated: 4/17/2014 1:55:09 AM
4. DOW30+    Part 4    195 Stocks    Updated: 4/17/2014 1:59:27 AM
 
5. ENERGY    Part 1    188 Stocks    Updated: 11/21/2013 2:38:12 AM
6. ENERGY    Part 2    186 Stocks    Updated: 11/21/2013 12:28:02 PM
7. ENERGY    Part 3    196 Stocks    Updated: 11/21/2013 12:32:34 PM
 
8. HEALTH    Part 1    184 Stocks    Updated: 4/16/2014 2:02:40 AM
9. HEALTH    Part 2    138 Stocks    Updated: 4/16/2014 2:07:27 AM
 
10. FINANCE    Part 1    191 Stocks    Updated: 11/13/2013 10:58:43 AM
11. FINANCE    Part 2    193 Stocks    Updated: 11/13/2013 12:29:31 PM
12. FINANCE    Part 3    188 Stocks    Updated: 11/13/2013 12:42:47 PM
13. FINANCE    Part 4    188 Stocks    Updated: 11/13/2013 12:46:35 PM
14. FINANCE    Part 5    190 Stocks    Updated: 11/13/2013 10:52:57 AM
 
15. SERVICE    Part 1    181 Stocks    Updated: 11/12/2013 11:38:45 PM
16. SERVICE    Part 2    186 Stocks    Updated: 11/12/2013 11:43:21 PM
17. SERVICE    Part 3    183 Stocks    Updated: 11/12/2013 11:48:07 PM
18. SERVICE    Part 4    193 Stocks    Updated: 11/12/2013 11:53:13 PM
 
19. TECH    Part 1    187 Stocks    Updated: 4/17/2014 11:25:01 PM
20. TECH    Part 2    183 Stocks    Updated: 4/17/2014 11:29:45 PM
21. TECH    Part 3    185 Stocks    Updated: 4/17/2014 11:34:24 PM
22. TECH    Part 4    102 Stocks    Updated: 4/17/2014 11:37:10 PM
 
23. IPOs    200 Stocks    Updated: 4/16/2014 2:54:58 PM
 
24. ETFs    Part 1    200 Stocks    Updated: 11/18/2013 12:58:25 AM
25. ETFs    Part 2    200 Stocks    Updated: 11/18/2013 1:04:02 AM
26. ETFs    Part 3    6 Stocks    Updated: 11/18/2013 1:10:14 AM

BUY  DOW 30+:    ENERGY: RNG  FMI  CDW  CBA  GDEF     HEALTH: EWN  EPP  NYC  TOK  IWW 
      FINANCE: XHB  XLI  SHM  XTN  GURU     SERVICES: BRAQ  ASEA  MLPJ  CHIM  PERM     TECH: CSGP  WDC  ONNN  RENN  JNPR 
SELL  DOW 30+: GGB     ENERGY: CHGG  ADMA  EVOK  BLUE  HASI     HEALTH: GNMA 
      FINANCE: ICOL  LEDD  JJG  GREK  VXX     SERVICES: CNPF     TECH: BRKR  CPHD  IPGP  LLTC  MDRX 


Samples of StockRing Real Time "Buy-Sell-Hold" stock Ratings:



  Enter Stock:  
  
    
    
 
 



Download StockRing Free  Buy-Sell-Hold iPhone
App for 1,200 stocks in Energy Healthcare Finance Services & Tech


DOW 30+

ENERGY

HEALTH

FINANCE

SERVICES

TECH

BUY  DOW 30+:    ENERGY: YUME  WPT  VJET  TRMR  THST     HEALTH: VEGI  USMV  URTH  TZY  TZW 
      FINANCE: XVZ  XTN  XSW  XRT  XPH     SERVICES: PERM  MLPJ  CHIM  BRAQ  ASEA     TECH: WDC  SWIR  RENN  ONNN  NTAP 
SELL  DOW 30+: GGB     ENERGY: ZU  XGTI  WUBA  WLH  TXTR     HEALTH: GNMA 
      FINANCE: VXX  SGG  SGAR  LEDD  JJG     SERVICES: CNPF     TECH: YNDX  XRX  XLNX  WIT  WCC 

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

Our FREE iPhone App with Buy-Sell-Hold ratings for 4,030 stocks:

  iPhone App Buy-Sell-Hold Ratings for 5-5-2013
           
           
           
           
     
  

 
  Enter Stock:  
  
    
    
 



4/18/2014  Friday, April 18, 2014 (Irvine, California) Today StockRing.com Recommendation is to "BUY"for Merck & Compan (NASDAQ:MRK) Stock. MRK stock opening price was $56.45 per share. Current price of NASDAQ:MRK Stock is $56.47 per share and it is $+0.21, (+0.37%) today and it was trading in the daily range of $250190 per share. Current Bid Price for (NASDAQ:MRK) stock is $3.09 and the Ask Price is $56.20. In the last 52 weeks MRK stock was trading in the range of $44.60 - 58.14. 50-Day Moving Average for (NASDAQ:MRK) stock is $15.668B and 200-Day Moving Average is $56.17. On average analysts predict that One Year Target Estimated price for (NASDAQ:MRK) stock is $51.46.

Merck & Compan (NASDAQ:MRK) is rated as a buy on 4/17/2014 1:36:28 AM.

Merck & Compan (NASDAQ:MRK) Market capitalization is $166.1B. (NASDAQ:MRK) stock average daily volume is N/A shares per day. However, on last trading session of Apr 17, 2012 MRK stock traded 11,263,810 shares. Also The Number of days it would take short sellers on average to repurchase all the borrowed shares or Short Ratio for (NASDAQ:MRK) stock is 44.033B. On previous trading session MRK Stock closed at $56.26 per share.

Last year Merck & Compan (NASDAQ:MRK) before taxes (EBITDA) (ttm) earned $57.01 on total revenue of $3.31. Earnings Per Share - EPS (ttm) for MRK stock is 1.47. Also, (NASDAQ:MRK) Stock Price Per Earnings ratio - P/E is 38.27. Thus, (NASDAQ:MRK) Stock Price/Sales (ttm) ratio is 57.44 and Price/Book (mrq) ratio is 3.76.

(NASDAQ:MRK) Stock pays a dividend of $ " per share which is a yield of "NYSE"%. So at this time (NASDAQ:MRK) Stock maintains Trailing Annual Dividend Rate at 2.50.


StockRing Recommendations for Merck & Compan (NASDAQ:MRK) Stock are updated daily here

http://StockRing.com/sr/Buy-Sell-Hold-Stock-Analysis-Ratings.asp?StockName=MRK

At this time StockRing recommends to buy LONG positions on many stocks from Dow 30+ stocks that currently have a BUY or SUPER BUY rating. If you decide to take a SHORT position and actually sell some stocks sjort right now - please check the section of Dow 30+ stocks that have a SELL or SUPER SELL rating.

If you would like to receive Buy-Sell-Hold ratings for stocks from Energy, Healthcare, Finance, Services & Hi-Tech sectors on your iPhone, then please download Buy-Sell-Hold iPhone App here:


Free Limited or $10 Full Version  Buy-Sell-Hold iPhone App
for 1,200 stocks in Energy, Healthcare, Finance, Services and Tech


DOW 30+

ENERGY

HEALTH

FINANCE

SERVICES

TECH


 
  Enter Stock:  
  
    
    
 
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

NASDAQ:MRK Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max    Options   More Info

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

4/18/2014 1 Year Stock market price chart for Merck & Compan (NASDAQ:MRK) Stock on Friday, April 18, 2014
  
1 Year MRK 1 Year Dow Jones
1 Year Nasdaq 1 Year S&P 500
4/18/2014 5 days Stock market price chart for Merck & Compan (NASDAQ:MRK) Stock on Friday, April 18, 2014
  
5 Days MRK 5 Days Dow Jones
5 Days Nasdaq 5 Days S&P 500
  

EUROs for $1 DOLLAR: 30 days
     

NASDAQ:MRK Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max    Options   More Info
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

4/18/2014 Stock market price quote data for Merck & Compan (NASDAQ:MRK) Stock on Friday, April 18, 2014

Last Trade: 56.47
Trade Time: Apr 17
Change: +0.21, (+0.37%)
Prev Close: 56.26
Open: 56.45
Bid: 3.09
Ask: 1.74
1y Target Est: $51.46
50-Day Moving Average: 15.668B
200-Day Moving Average:
56.17
Short Ratio: 44.033B
Trailing Annual Dividend Rate: 2.50
Day's Range: 250190
52wk Range: 44.60 - 58.14
Volume: 11,263,810
Avg Vol: N/A
Market Cap: 166.1B
P/E (ttm): 38.27
EPS (ttm): 1.47
Div & Yield: " ("NYSE"%)
Revenue (ttm): 3.31
Earnings before Tax (EBITDA) (ttm): 57.01
Price/Sales (ttm): 57.44
Price/Book (mrq): 3.76
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

  
  
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

MERCK CO INC(NYSE: MRK) Company Information

Merck & Co. Inc.
PO Box 100
One Merck Drive
Whitehouse Station, NJ 08889-0100
United States - Map
Phone: 908-423-1000
Fax: 908-735-1253
Web Site: http://www.merck.com

MERCK CO INC(NYSE: MRK) DETAILS

MERCK CO INC(NYSE: MRK) Index Membership: Dow Jones Composite Dow Industrials S&P 100 S&P 500 S&P 1500 Super Comp
MERCK CO INC(NYSE: MRK) Sector: Healthcare
MERCK CO INC(NYSE: MRK) Industry: Drug Manufacturers - Major
MERCK CO INC(NYSE: MRK) Full Time Employees: 52,700

MERCK CO INC(NYSE: MRK) BUSINESS SUMMARY

Merck & Co., Inc. provides products for human and animal health in the United States and internationally. The company?s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Januvia and Janumet for type 2 diabetes; Cosopt and Trusopt, the ophthalmological products; Zocor, an atherosclerosis product; Maxalt for acute migraine; Propecia to treat male pattern hair loss; Arcoxia to treat arthritis and pain; Proscar to treat symptomatic benign prostate enlargement; and Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting. Merck & Co.?s Vaccines segment comprises human health vaccines, such as preventative pediatric, adolescent, and adult vaccines. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; M-M-R II, a vaccine against measles, mumps, and rubella; RotaTeq to protect against rotavirus gastroenteritis in children; Zostavax for preventing shingles; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Isentress, Crixivan, and Stocrin, antiretroviral therapies for the treatment of HIV infection; and Invanz for the treatment of infection. Merck & Co. has research, collaboration, or licensing agreements with Neuromed Pharmaceuticals, Ltd.; ARIAD Pharmaceuticals, Inc.; GTX, Inc.; Idera Pharmaceuticals; Japan Tobacco Inc.; Galapagos NV; AstraZeneca plc; Metabasis Therapeutics Inc.; and Addex Pharmaceuticals Ltd. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

MERCK CO INC(NYSE: MRK) KEY EXECUTIVES

Mr. Richard T. Clark , 63 Exec. Chairman, Chief Exec. Officer and Pres $ 4.03M $ 0

Mr. Peter N. Kellogg , 52 Chief Financial Officer and Exec. VP $ 1.60M $ 0

Mr. Kenneth C. Frazier , 54 Exec. VP and Pres of Global Human Health $ 2.00M $ 0

Dr. Peter Kim Ph.D., 50 Exec. VP and Pres of Merck Research Laboratories $ 1.91M $ 0

Mr. Bruce N. Kuhlik , 52 Exec. Vice president and Gen. Counsel $ 1.25M $ 0



4/18/2014 Latest stock market news data for Merck & Compan (NASDAQ:MRK) Stock on Friday, April 18, 2014

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Motley Fool - 23 hours ago
No drug has hit the market running like Gilead Sciences' (NASDAQ: GILD ) freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory approval ...
Drugmaker Studies Find a Bargain in $84000 Medicine - Bloomberg
Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences ...
Motley Fool - Apr 15, 2014
While leader Gilead Sciences (NASDAQ: GILD ) waits on the FDA review for its combination of Sovaldi and levipasvir, and battles questions over Sovaldi's price tag, Merck is producing data on easy-to-treat populations and Bristol-Myers Squibb has turned ...
One Put, One Call Option To Know About For Merck & Co.
TheStreet.com - Apr 14, 2014
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (MRK). So this week we highlight one interesting put contract, and one interesting call contract, from the May ...
Merck & Co., Inc. (NYSE:MRK) Reports Positives on its Hepatitis Treatment
USTrade Voice - Apr 11, 2014
Dallas, Texas 04/11/2014 (ustradevoice) - Merck & Co., Inc. (NYSE:MRK) continues to surge in the market after the company announced positive news, on the progress being made on the development of its hepatitis C combo therapies MK-5172 AND ...
Merck Hepatitis C combo pill impresses in Phase II - Seeking Alpha
Merck Data Show Potent Rival to Gilead's Hepatitis C Pill - Bloomberg
Stocks to Watch Friday: Merck & Co., Inc., Deere & Company, and Toyota Motor ...
Schaeffers Research (blog) - Apr 10, 2014
Momentum names that made notable moves on Thursday and could continue to do so into Friday's session include pharmaceutical firm Merck & Co., Inc. (NYSE:MRK), machinery concern Deere & Company (NYSE:DE), and automaker Toyota Motor Corp ...
Drug Most active stocks: Pfizer Inc. (NYSE:PFE), Merck & Co (NYSE:MRK ... - Gaining Green
Merck & Co. Price Target Increased to $70.00 by Analysts at MKM Partners (MRK) - Ticker Report
Brand Face-Off: GlaxoSmithKline plc (ADR) vs. Merck & Co., Inc.
Schaeffers Research - Apr 7, 2014
Pharmaceutical giants GlaxoSmithKline plc (ADR) (NYSE:GSK) and Merck & Co., Inc. (NYSE:MRK) have charted different paths during the last year.
Insider Selling: Merck & Co. Insider Unloads 145225 Shares of Stock (MRK) - Ticker Report
Merck & Co., Inc. (NYSE:MRK)'s Oncology Break-Through MK-3475 Said To ...
WallStreetPR - Apr 9, 2014
It is the case with the breakthrough drug from Merck & Co., Inc. (NYSE:MRK) called the MK-3475 that provides efficient results in the treatment of non-small cell lung cancer (NSCLC).
Merck & Co., Inc. (NYSE:MRK) Presents Immunotherapy Findings; Collaborates ...
WallStreetPR - Apr 7, 2014
Boston, MA 04/07/2014 (wallstreetpr) - Yesterday, Merck & Co., Inc. (NYSE:MRK) provided early discoveries associated with the relation between PD-L1 Expression and the clinical outcome of its under study Anti-PD-1 Immunotherapy, MK-3475 at AACR ...
Merck: Is The Dow's YTD Leader A Long-Term Buy?
Seeking Alpha - Apr 1, 2014
Merck & Co., Inc. (MRK) is one of the world's largest pharmaceutical companies in the world that develops prescription medicines, vaccines, and consumer care products.
Merck & Co. PT Raised to $70.00 at MKM Partners (MRK)
WKRB News - Apr 14, 2014
Merck & Co., Inc. logo Merck & Co. (NYSE:MRK) had its target price boosted by MKM Partners from $64.00 to $70.00 in a report issued on Friday, Analyst Ratings Network.
Merck & Co. CEO Kenneth Frazier Sells 10047 Shares (MRK) - Mideast Time

 
DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   


Biggest Movers in Healthcare Stocks Now ALXN MRK GILD XRAY
Investorplace.com
Merck & Company (MRK): MRK stock is up 1.2%, marking the third consecutive day the stock has increased. Gilead Sciences (GILD): GILD stock is up 0.6%, marking the fifth consecutive day the stock has increased. Dentsply International Inc (XRAY): XRAY ...


Bidness Etc

Why Merck (MRK) Stock Is Higher This Morning
TheStreet.com
"We rate MERCK & CO (MRK) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its largely ...
Merck's Hepatitis C Drug Makes Important ProgressBidness Etc
Gilead Risks Beyond Just Merck: Serious Chart Violation Watch24/7 Wall St.
3 Biotech Companies That Look To Be Good Buys After A PullbackSeeking Alpha
Motley Fool -Bloomberg
all 222 news articles »

Hottest Healthcare Stocks Now WMGI PDLI GB MRK
Investorplace.com
Merck & Company (MRK): MRK stock is up 1.4% to a new 52-week high of $57.91. Shire Plc American Depositary Shares (SHPG): SHPG stock is up 1.2%, marking the third consecutive day the stock has increased. Intuitive Surgical (ISRG): ISRG stock is up ...


Merck & Co. PT Raised to $70.00 at MKM Partners (MRK)
WKRB News
(NYSE:MRK) had its target price boosted by MKM Partners from $64.00 to $70.00 in a report issued on Friday, Analyst Ratings Network.com reports. They currently have a buy rating on the stock. MRK has been the subject of a number of other recent ...
Merck & Co. CEO Kenneth Frazier Sells 10047 Shares (MRK)Mideast Time

all 3 news articles »

Dow Today: Merck (MRK) Leads The Day Higher, Exxon Mobil Corporation ...
TheStreet.com
The Dow component leading the way higher looks to be Merck (NYSE:MRK), which is sporting an 86-cent gain (+1.6%) bringing the stock to $55.90. This single gain is lifting the Dow Jones Industrial Average by 6.51 points or roughly accounting for 19.7 ...

and more »

Interesting January 2016 Stock Options for MRK
NASDAQ
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (Symbol: MRK). So this week we highlight one interesting put contract, and one interesting call contract, from the ...

and more »

Dow Today: Merck (MRK) Leads The Day Higher, Chevron (CVX) Lags
TheStreet.com
The Dow component leading the way higher looks to be Merck (NYSE:MRK), which is sporting a 65-cent gain (+1.1%) bringing the stock to $57.75. Volume for Merck currently sits at 1.9 million shares traded vs. an average daily trading volume of 13 million ...

and more »

Interesting July Stock Options for MRK
NASDAQ
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (Symbol: MRK). So this week we highlight one interesting put contract, and one interesting call contract, from the ...

and more »

Insider Selling: Merck & Co. Insider Unloads 145225 Shares of Stock (MRK)
Ticker Report
Merck & Co. logo Merck & Co. (NYSE:MRK) Insider Bruce Kuhlik unloaded 145,225 shares of Merck & Co. stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $56.43, for a total value of $8,195,046.75. Following the ...
Brand Face-Off: GlaxoSmithKline plc (ADR) vs. Merck & Co., Inc.Schaeffers Research

all 2 news articles »

Money Morning

Endocyte, Merck Cancer Drug Scores Twice
Investor's Business Daily
Biotech Endocyte (ECYT) and its big-pharma partner Merck (MRK) got a double dose of good news on their cancer drug vintafolide Friday, more than doubling Endocyte's stock on the stock market today. First, the European Medicines Agency's advisory ...
Endocyte, Inc. Still Has Huge Potential Post-90% PopMotley Fool
Endocyte (ECYT) Doubles on Successful Vintafolide TrialEquities.com
This Cutting-Edge Drug Has Endocyte (Nasdaq: ECYT) Stock SoaringMoney Morning
TheStreet.com -FierceBiotech
all 80 news articles »

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs


4/18/2014 News from StockRing Blog about Merck & Compan (NASDAQ:MRK) Stock on Friday, April 18, 2014



Copyright © 2012 StockRing.com. All rights reserved.
Subscriber Agreement   Privacy Agreement   Stocks   MutualFunds

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither StockRing.com nor its partners shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the StockRing site, a user agrees not to redistribute the information found therein.